<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11625">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02955602</url>
  </required_header>
  <id_info>
    <org_study_id>CB8025-21629</org_study_id>
    <nct_id>NCT02955602</nct_id>
  </id_info>
  <brief_title>MBX-8025 in Subjects With Primary Biliary Cholangitis (PBC) (8 Week, Dose Ranging, Open Label, Randomized Phase 2 With an Extension)</brief_title>
  <official_title>An 8-week, Dose Ranging, Open Label, Randomized, Phase 2 Study With an 18-week Extension, to Evaluate the Safety and Efficacy of MBX-8025 in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or Intolerance to Ursodeoxycholic Acid (UDCA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CymaBay Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CymaBay Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An 8-week, dose ranging, open label, randomized, Phase 2 study with an 18-week extension, to
      evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis
      (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary:

      To evaluate the safety and efficacy of MBX-8025 5 mg, 10 mg, and 25 mg over 8 weeks of
      treatment

      Secondary:

      To evaluate the safety and efficacy of MBX-8025 5 mg, 10 mg, and 25 mg over 26 weeks of
      treatment

      To evaluate the pharmacokinetics (PK) of MBX-8025

      Exploratory:

      To evaluate the effect of MBX-8025 on bile acids, additional markers of inflammation and
      renal function
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Alkaline Phosphatase (AP)</measure>
    <time_frame>over 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AE) and Treatment Emergent Adverse Events (TEAEs), ECG, biochemistry, hematology and urinalysis (NCI CTCAE Version 4.0)</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST)</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT)</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gamma-glutamyl Transferase (GGT)</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5'nucleotidase</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin - Total Bilirubin</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin - Conjugated Bilirubin</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin - Unconjugated Bilirubin</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Specific Alkaline Phosphatase (AP)</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides (TG)</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol (TC)</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of AP and Total Bilirubin</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
    <description>AP &lt; 1.67 × upper limit of normal (ULN)
Total Bilirubin within normal limit
&gt; 15% decrease in AP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC Response Criteria - Paris I</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC Response Criteria - Paris II</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC Response Criteria - Toronto I</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC Response Criteria - Toronto II</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC Response Criteria - UK-PBC Risk Score</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5D-itch Scale</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus Visual Analog Score (VAS)</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PBC-40 Quality of Life (QoL)</measure>
    <time_frame>over 8 weeks and over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Alkaline Phosphatase (AP)</measure>
    <time_frame>over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of MBX-8025 and Metabolites</measure>
    <time_frame>(at 0, 0.5, 1, 2, 4, 6 and 24 hours for Cmax, Tmax, T1/2 and AUC)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>MBX-8025 (5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBX-8025 5 mg capsule once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-8025 (10 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBX-8025 10 mg capsule once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-8025 (25 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBX-8025 25 mg capsule once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-8025 5 mg Capsule</intervention_name>
    <description>Open label, randomized, uncontrolled, 8-week treatment with the potential to titrate up to 10 mg or to 25 mg in the extension period for up to 26 weeks.</description>
    <arm_group_label>MBX-8025 (5 mg)</arm_group_label>
    <other_name>MBX-8025</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-8025 10 mg Capsule</intervention_name>
    <description>Open label, randomized, uncontrolled, 8-week treatment with the potential to titrate up or down to 5 mg or to 25 mg in the extension period for up to 26 weeks.</description>
    <arm_group_label>MBX-8025 (10 mg)</arm_group_label>
    <other_name>MBX-8025</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-8025 25 mg Capsule</intervention_name>
    <description>Open label, randomized, uncontrolled, 8-week treatment with the potential to titrate down to 5 mg or to 10 mg in the extension period for up to 26 weeks.
Open label extension for a total of up to 26-week treatment</description>
    <arm_group_label>MBX-8025 (25 mg)</arm_group_label>
    <other_name>MBX-8025</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must have given written informed consent (signed and dated) and any authorizations
             required by local law

          2. 18 to 75 years old (inclusive)

          3. Male or female with a diagnosis of PBC, by at least two of the following criteria:

               -  History of AP above ULN for at least six months

               -  Positive AMA titers (&gt;1/40 on immunofluorescence or M2 positive by enzyme linked
                  immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies

               -  Documented liver biopsy result consistent with PBC

          4. On a stable and recommended dose of UDCA for the past twelve months or intolerant to
             UDCA

          5. AP ≥ 1.67 × ULN

          6. Females of reproductive potential must use at least one barrier contraceptive and a
             second effective birth control method during the study and for at least 90 days after
             the last dose. Male subjects who are sexually active with female partners of
             reproductive potential must use barrier contraception and their female partners must
             use a second effective birth control method during the study and for at least 90 days
             after the last dose

        Exclusion Criteria:

          1. A medical condition, other than PBC, that in the investigator's opinion would
             preclude full participation in the study or confound its results (e.g., cancer on
             active treatment)

          2. AST or ALT &gt; 3 × ULN

          3. Total bilirubin &gt; 2.0 mg/dL

          4. Auto-immune hepatitis

          5. Primary sclerosing cholangitis

          6. Known history of alpha-1-Antitrypsin deficiency

          7. Known history of chronic viral hepatitis or HIV infection

          8. Creatine kinase above ULN

          9. Serum creatinine above ULN

         10. For females, pregnancy or breast-feeding

         11. Use of colchicine, methotrexate, azathioprine, or systemic steroids in the two months
             preceding screening

         12. Current use of fibrates or simvastatin

         13. Current use of obeticholic acid

         14. Current use of an experimental or unapproved treatment for PBC

         15. Current use of experimental or unapproved immunosuppressant

         16. Adverse event leading to MBX-8025 discontinuation from CymaBay's phase 2 PBC study
             (CB8025-21528)

         17. Hepatic decompensation (e.g., known history of esophageal variceal bleed, ascites,
             hepatic encephalopathy)

         18. Acute pancreatitis or known history of chronic pancreatitis

         19. Any other condition(s) that would compromise the safety of the subject (e.g.,
             uncontrolled diabetes, uncontrolled hypertension, severe osteoporosis) or compromise
             the quality of the clinical study (e.g., subjects with drug or alcohol abuse), as
             judged by the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pol F Boudes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CymaBay Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pol F Boudes, MD</last_name>
    <phone>510-293-8815</phone>
    <email>PBoudes@cymabay.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra (Sasha) Steinberg, MD, PhD</last_name>
    <phone>510-293-8817</phone>
    <email>ASteinberg@cymabay.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarek Hassanein, MD</last_name>
      <phone>619-990-1698</phone>
      <email>THassanein@livercenters.com</email>
    </contact>
    <contact_backup>
      <last_name>Julio Gutierrez, MD</last_name>
      <phone>646-345-2492</phone>
      <email>jgutierrez@livercenters.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Bowlus, MD</last_name>
      <phone>916-734-3751</phone>
      <email>clbowlus@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Souvik Sarkar, MD</last_name>
      <phone>917-451-8911</phone>
      <email>ssarkar@ucdavis.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Miami - Center for Liver Diseases</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Levy, MD</last_name>
      <phone>305-243-2330</phone>
    </contact>
    <contact_backup>
      <last_name>Eugene Schiff, MD</last_name>
      <phone>305-243-4615</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastroenterology Associates, LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norman Gitlin, MD</last_name>
      <phone>404-881-1094</phone>
    </contact>
    <contact_backup>
      <last_name>Cathy Williams, PA-C</last_name>
      <phone>404-881-1094</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Digestive Healthcare of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael R Galambos, MD</last_name>
      <phone>404-355-3200</phone>
    </contact>
    <contact_backup>
      <last_name>Mark A Sims, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Thuluvath, MD</last_name>
      <phone>410-332-9308</phone>
      <email>thuluvath@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Anurag Maheshwari, MD</last_name>
      <phone>410-332-9308</phone>
      <email>amahesh@mdmercy.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart C Gordon, MD</last_name>
      <phone>313-916-9465</phone>
      <email>sgordon3@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Pamela Drury, NP</last_name>
      <phone>313-283-0708</phone>
      <email>pdrury1@hfhs.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Borg, MD</last_name>
      <phone>601-984-4542</phone>
      <email>bborg@umc.edu</email>
    </contact>
    <contact_backup>
      <last_name>John Sheehan, MD</last_name>
      <phone>318-547-1577</phone>
      <email>Johnsheehanmd01@comcast.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Saint Louis University, Gastroenterology &amp; Hepatology</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Bacon, MD</last_name>
      <phone>314-577-8764</phone>
      <email>baconcr@slu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health - Center for Liver Disease and Transplantation</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Bernstein, MD</last_name>
      <phone>516-562-4664</phone>
    </contact>
    <contact_backup>
      <last_name>Tai-Ping Lee, MD</last_name>
      <phone>516-562-4664</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Stancia, MD</last_name>
      <phone>646-929-7870</phone>
      <email>carmenstanca@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>David Feldman, MD</last_name>
      <phone>646-929-7870</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Odin, MD</last_name>
      <phone>212-241-6696</phone>
    </contact>
    <contact_backup>
      <last_name>Nancy Bach, MD</last_name>
      <phone>(212) 241-6696</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John M Vierling, MD</last_name>
      <phone>713-798-4951</phone>
    </contact>
    <contact_backup>
      <last_name>Rise J Stribling, MD</last_name>
      <phone>(713) 798-4951</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Consultants of SA</name>
      <address>
        <city>Live Oak</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen A Harrison, MD</last_name>
      <phone>210-614-1234</phone>
      <email>DrHarrison@gastroconsa.com</email>
    </contact>
    <contact_backup>
      <last_name>Hays L Arnold, MD</last_name>
      <phone>210-614-1234</phone>
      <email>DrArnold@gastroconsa.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Bon Secours St. Mary's Immaculate Hospital</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Shiffman, MD</last_name>
      <phone>804-285-2011</phone>
    </contact>
    <contact_backup>
      <last_name>Nadege Gunn, MD</last_name>
      <phone>(804) 285-2011</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Calgary Liver Unit</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Swain, M.D.</last_name>
      <phone>403-592-5011</phone>
      <email>swain@ucalgary.ca</email>
    </contact>
    <contact_backup>
      <last_name>Meredith Borman, M.D.</last_name>
      <phone>403-210-3800</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Toronto Centre for Liver Disease</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hemant Shah, MD</last_name>
      <phone>416-340-4946</phone>
      <email>hemant.shah@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jordan Feld, MD</last_name>
      <phone>416-340-4584</phone>
      <email>jordan.feld@uhn.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Outpatient Clinic of Internal Medicine</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Dorffel, MD</last_name>
      <phone>(+49) 30450514018</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Kremer, MD</last_name>
      <phone>+49 (0)9131 85-45015</phone>
      <email>andreas.kremer@uk-erlangen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ifi-Studien und Projekte GmbH, An der Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Buggisch, MD</last_name>
      <phone>+49 40 28407600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center of Internal Medicine - Medical School of Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Manns, MD</last_name>
      <phone>+49 511 5320</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Centre of the Johannes Guttenberg-University</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Worns, MD</last_name>
      <email>marcus-alexander.woerns@unimedizin-mainz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitatsklinik Tubingen</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Berg, MD</last_name>
      <phone>07071 29-82712</phone>
    </contact>
    <contact_backup>
      <last_name>Thomas Klag, MD</last_name>
      <phone>07071 29-82712</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gideon Hirschfield, MD</last_name>
      <phone>+44 121 627 2000</phone>
    </contact>
    <contact_backup>
      <last_name>Katherine Amdtz, MD</last_name>
      <phone>+44 121 627 2000</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hull and East Yorkshire Hospitals NHS Trust</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynsey Corless, MD</last_name>
      <phone>01482 816797</phone>
      <email>Lynsey.corless@hey.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>George Abouda, MD</last_name>
      <phone>01482 816776</phone>
      <email>George.Abouda@hey.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Plymouth Hospitals NHS Trust</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Sheridan, MD</last_name>
      <phone>01752 792725</phone>
      <email>david.sheridan2@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 7, 2017</lastchanged_date>
  <firstreceived_date>November 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PBC</keyword>
  <keyword>Primary Biliary Cholangitis (PBC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
